Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
LOC
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1
EP3781157A1
METHODS OF TREATING NEUROPATHIC PAIN
Publication/Patent Number: EP3781157A1 Publication Date: 2021-02-24 Application Number: 19787899.4 Filing Date: 2019-04-12 Inventor: Zhao, Yuan   Naik, Himanshu   Assignee: Biogen MA Inc.   IPC: A61K31/401
2
US10955422B2
Method of assessing risk of PML
Publication/Patent Number: US10955422B2 Publication Date: 2021-03-23 Application Number: 15/120,573 Filing Date: 2015-02-27 Inventor: Plavina, Tatiana   Carulli, John P.   Gorelik, Leonid   Compton, Teresa   Assignee: Biogen MA, Inc.   IPC: G01N33/53 Abstract: The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).
3
US11040119B2
Compositions and methods for assessing neuromuscular function
Publication/Patent Number: US11040119B2 Publication Date: 2021-06-22 Application Number: 14/774,510 Filing Date: 2014-03-12 Inventor: Verma, Ajay   Hoppin, Jack   Assignee: Biogen MA Inc.   IPC: A61K51/04 Abstract: The invention provides compositions and methods for evaluating neuromuscular function in a subject, e.g., a subject at risk for or suffering from a neuromuscular disorder.
4
US2021246212A1
ANTI-GPIIB/IIIA ANTIBODIES AND USES THEREOF
Publication/Patent Number: US2021246212A1 Publication Date: 2021-08-12 Application Number: 17/096,458 Filing Date: 2020-11-12 Inventor: Salas, Joe   Hanf, Karl   Van, Der Flier Arjan   Pearse, Bradley R.   Assignee: Biogen MA Inc.   IPC: C07K16/28 Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.
5
US11083791B2
Anti-VLA-4 antibodies
Publication/Patent Number: US11083791B2 Publication Date: 2021-08-10 Application Number: 16/441,974 Filing Date: 2019-06-14 Inventor: Lugovskoy, Alexey A.   Taylor, Frederick R.   Mclachlan, Karen   Assignee: Biogen MA Inc.   IPC: A61K39/395 Abstract: This invention relates to alpha-4 binding antibodies, and fragments thereof.
6
EP3875450A1
NRF2 ACTIVATOR
Publication/Patent Number: EP3875450A1 Publication Date: 2021-09-08 Application Number: 21152411.1 Filing Date: 2017-12-27 Inventor: Lucas, Brian Stuart   Lin, Edward Yin-shiang   Capacci, Andrew George   Xin, Zhili   Enyedy, Istvan   Chen, Teyu   Jones, John H.   Van, Vloten Kurt D.   Assignee: Biogen MA Inc.   IPC: C07D217/04 Abstract: Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.
7
EP3891146A1
MORPHOLINYL, PIPERAZINYL, OXAZEPANYL AND DIAZEPANYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS
Publication/Patent Number: EP3891146A1 Publication Date: 2021-10-13 Application Number: 19828102.4 Filing Date: 2019-12-04 Inventor: Genung, Nathan   Guckian, Kevin M.   Vessels, Jeffrey   Zhang, Lei   Gianatassio, Ryan   Lin, Edward Yin Shiang   Xin, Zhili   Assignee: Biogen MA Inc.   IPC: C07D417/14
8
US2021228701A1
Dimethyl Fumarate and Vaccination Regimens
Publication/Patent Number: US2021228701A1 Publication Date: 2021-07-29 Application Number: 17/228,004 Filing Date: 2021-04-12 Inventor: Viglietta, Vissia   Assignee: Biogen MA Inc.   IPC: A61K39/09 Abstract: Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
9
US2021130397A1
METHODS FOR PURIFYING ANTIBODIES HAVING REDUCED HIGH MOLECULAR WEIGHT AGGREGATES
Publication/Patent Number: US2021130397A1 Publication Date: 2021-05-06 Application Number: 16/640,755 Filing Date: 2018-08-22 Inventor: Westoby, Matthew   Evangelist, Greg   Assignee: Biogen MA Inc.   IPC: C07K1/18 Abstract: Provided herein, in some embodiments, are methods and compositions for purifying antibodies from cellular cultures using one or more thiol containing additives during a purification process, for example in a chromatographic purification process.
10
US11007167B2
Methods of treating multiple sclerosis
Publication/Patent Number: US11007167B2 Publication Date: 2021-05-18 Application Number: 17/071,740 Filing Date: 2020-10-15 Inventor: Novas, Mark   Zhang, Rui (ray)   Assignee: Biogen MA Inc.   IPC: A61K31/225 Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
11
EP3782652A1
PEGYLATION METHOD
Publication/Patent Number: EP3782652A1 Publication Date: 2021-02-24 Application Number: 20180909.2 Filing Date: 2015-08-18 Inventor: Gronke, Robert S.   Jaquez, Orlando   Assignee: Biogen MA Inc.   IPC: A61K47/60 Abstract: The present invention relates to a method for PEGylating interferon beta.
12
US10913782B2
Hybrid ActRIIB ligand trap proteins for treating muscle wasting diseases
Publication/Patent Number: US10913782B2 Publication Date: 2021-02-09 Application Number: 15/568,232 Filing Date: 2016-04-12 Inventor: Han, Hq   Zhou, Xiaolan   Assignee: Biogen MA Inc.   IPC: C07K14/705 Abstract: The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides which fully retain binding affinity for myostatin and activin A but demonstrate significantly reduced binding to BMPs, especially BMP-9. The novel compositions described herein can be used to prepare novel hybrid ActRIIB ligand trap proteins, which can be used for modulating the growth of muscle, bone, cartilage, fat, fibroblast, blood and neuronal tissue to counteract muscle wasting, bone loss, anemia, inflammation and fibrosis in a therapeutically meaningful manner. Because these novel next-generation myostatin/activin inhibitors are safer and more effective molecules than the currently available myostatin inhibitors, they are useful in a wide variety of clinical indications.
13
US2021071176A1
COMPOSITIONS FOR MODULATING TAU EXPRESSION
Publication/Patent Number: US2021071176A1 Publication Date: 2021-03-11 Application Number: 16/986,770 Filing Date: 2020-08-06 Inventor: Kordasiewicz, Holly   Swayze, Eric E.   Freier, Susan M.   Bui, Huynh-hoa   Assignee: Biogen MA Inc.   IPC: C12N15/113 Abstract: Disclosed herein are antisense compounds and methods for decreasing Tau mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Tau-associated diseases, disorders, and conditions.
14
EP3750560A3
COMBINATION THERAPIES AND USES FOR TREATMENT OF DEMYELINATING DISORDERS
Publication/Patent Number: EP3750560A3 Publication Date: 2021-03-24 Application Number: 20173044.7 Filing Date: 2013-10-08 Inventor: Cadavid, Diego   Mi, Sha   Assignee: Biogen MA Inc.   IPC: A61K39/395 Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.
15
US2021309719A1
ARGININE-FREE TNFR:FC-FUSION POLYPEPTIDE COMPOSITIONS AND METHODS OF USE
Publication/Patent Number: US2021309719A1 Publication Date: 2021-10-07 Application Number: 17/216,769 Filing Date: 2021-03-30 Inventor: Maloney, Kevin   Gong, Ke   Alston, Roy   Assignee: Biogen MA Inc.   IPC: C07K14/715 Abstract: Aspects of the invention are directed to arginine-free polypeptide-containing compositions and methods for treating disorders associated with inflammation or the autoimmune response. In particular, the polypeptide is etanercept.
16
US2021315854A1
METHODS OF TREATING MULTIPLE SCLEROSIS
Publication/Patent Number: US2021315854A1 Publication Date: 2021-10-14 Application Number: 17/321,788 Filing Date: 2021-05-17 Inventor: Novas, Mark   Zhang, Rui (ray)   Assignee: Biogen MA Inc.   IPC: A61K31/225 Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
17
EP3405465B1
IRAK4 INHIBITING AGENTS
Publication/Patent Number: EP3405465B1 Publication Date: 2021-10-13 Application Number: 17703277.8 Filing Date: 2017-01-18 Inventor: Chan, Timothy   Guckian, Kevin   Jenkins, Tracy   Thomas, Jermaine   Vessels, Jeffrey   Kumaravel, Gnanasambandam   Meissner, Robert   Lyssikatos, Joseph P.   Lucas, Brian   Leaf, Irina   Duffield, Jeremy   Genung, Nathan   Assignee: Biogen MA Inc.   IPC: C07D401/14
18
US2021102939A1
ASSAY FOR JC VIRUS ANTIBODIES
Publication/Patent Number: US2021102939A1 Publication Date: 2021-04-08 Application Number: 16/594,843 Filing Date: 2019-10-07 Inventor: Gorelik, Leonid   Simon, Kenneth J.   Subramanyam, Meena   Rushe, Mia Marie   Assignee: Biogen MA Inc.   IPC: G01N33/543 Abstract: The disclosure relates to methods and reagents for analyzing samples for the presence of JC virus antibodies. Disclosed is a method that includes obtaining a biological sample from a subject (e.g., plasma, serum, blood, urine, or cerebrospinal fluid), contacting the sample with highly purified viral-like particles (HPVLPs) under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, and detecting the level of JCV antibody binding in the sample to HPVLP. In one embodiment, determining the level of anti-JCV antibodies in the subject sample provides a method of identifying PML risk in a subject.
19
EP3800999A1
ANTI-VLA-4 ANTIBODIES HAVING REDUCED EFFECTOR FUNCTION
Publication/Patent Number: EP3800999A1 Publication Date: 2021-04-14 Application Number: 19815783.6 Filing Date: 2019-05-31 Inventor: Ferrant-orgettas, Janine Lisa   Pepinsky, Robert Blake   Cahir-mcfarland, Ellen Duggan   D'lima, Nadia Giselle   Arndt, Joseph Walter   Hanf, Karl John Mortley   Cameron, Thomas Owen   Stark, Ellen Garber   Assignee: Biogen MA Inc.   IPC: A01H6/82
20
US2021025900A1
METHODS AND PRODUCTS FOR EVALUATING AN IMMUNE RESPONSE TO A THERAPEUTIC PROTEIN
Publication/Patent Number: US2021025900A1 Publication Date: 2021-01-28 Application Number: 16/923,043 Filing Date: 2020-07-07 Inventor: Subramanyam, Meena   Amaravadi, Lakshimi   Wakshull, Eric   Lynn, Frances   Panzara, Michael   Barbour, Robin Mcdaid   Taylor, Julie Elizabeth   Assignee: Biogen MA Inc.   IPC: G01N33/68 Abstract: The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).
Total 500 pages